What is the pathophysiology of multiple myeloma?

Pathophysiology of Multiple Myeloma

Multiple myeloma is a clonal malignancy of late-stage B-cells that transform into malignant plasma cells, driven by primary genetic events (IgH translocations or hyperdiploidy) followed by secondary mutations that enable uncontrolled proliferation, bone marrow accumulation, and interaction with the microenvironment leading to bone destruction, immune suppression, and organ damage 1.

Cellular Origin and Initial Transformation

The disease originates from a B-lymphocyte that acquires aberrant genomic events in the germinal center of lymph nodes during somatic hypermutation and class-switch recombination driven by activation-induced deaminase 2. These are off-target events that occur during normal B-cell maturation, transforming the cell into a malignant clone that eventually homes to and accumulates in the bone marrow 3, 4.

Primary Genetic Events: The Foundation

At the highest hierarchical level, myeloma divides into two major genetic subtypes 1:

Non-Hyperdiploid Myeloma (45-50% of cases)

• Characterized by IgH translocations that dysregulate key oncogenes
• The three main translocations are:
  • t(11;14)(q13;q32): Dysregulates CCND1 (cyclin D1)
  • t(4;14)(p16;q32): Dysregulates NSD2/FGFR3
  • t(14;16)(q32;q23): Dysregulates MAF family genes
• Additional translocations involve CCND3 on 6p21, CCND2 on 12q11, MAFB on 20q11, or MAFA on 8q24 4
• Generally associated with more aggressive clinical features and shorter survival 1

Hyperdiploid Myeloma (50-55% of cases)

• Characterized by trisomies of odd-numbered chromosomes (typically chromosomes 3,5,7,9,11,15,19,21)
• Associated with a more indolent clinical course 1
• No primary IgH translocations present

Secondary Genetic Events: Disease Progression

After the primary initiating events, additional genetic abnormalities drive progression from asymptomatic stages (MGUS, smoldering myeloma) to symptomatic disease 4, 2:

• Chromosome 13 deletion (del13q): Associated with disease progression
• Chromosome 17 deletion (del17p): Loss of TP53 tumor suppressor gene, highly adverse prognosis
• Chromosome 1 abnormalities:
  • 1p deletion (loss of tumor suppressors)
  • 1q amplification/gain (associated with aggressive disease)
• MYC dysregulation: Drives proliferation and disease aggressiveness
• RAS pathway mutations (NRAS, KRAS): Activate proliferative signaling
• NFκB pathway activation: Promotes plasma cell survival
• Cell cycle pathway mutations: Loss of function in tumor suppressors like CDKN2A/B 1, 4

Bone Marrow Microenvironment Interactions

The relationship between malignant plasma cells and the bone marrow microenvironment is critical for disease manifestation and progression 5, 6:

Bone Destruction Mechanisms

• Osteoclast activation: Malignant plasma cells secrete factors (RANKL, MIP-1α, IL-6) that stimulate osteoclast differentiation and activity
• Osteoblast suppression: Secretion of DKK1 and other Wnt pathway inhibitors blocks bone formation
• Osteocyte dysfunction: Altered signaling contributes to the imbalance between bone resorption and formation
• Results in lytic bone lesions, pathological fractures, and hypercalcemia 5

Immune Microenvironment Dysregulation

• Malignant plasma cells create an immunosuppressive microenvironment
• Impaired T-cell function and natural killer cell activity
• Increased regulatory T-cells and myeloid-derived suppressor cells
• Contributes to immune evasion and increased infection risk 6, 7

Cytokine Networks

• IL-6: Primary growth and survival factor for myeloma cells
• VEGF: Promotes angiogenesis and disease progression
• TNF-α, IL-1β: Drive inflammatory responses and bone destruction
• These cytokines create a self-reinforcing loop supporting malignant cell survival 5, 6

Clinical Manifestations: The CRAB Criteria

The pathophysiological processes culminate in the classic CRAB features 3, 4:

• C (Calcium elevation): From osteoclast-mediated bone destruction
• R (Renal impairment): From light chain cast nephropathy, hypercalcemia, and other mechanisms
• A (Anemia): From bone marrow infiltration by plasma cells and cytokine-mediated suppression
• B (Bone disease): From the osteoclast/osteoblast imbalance described above

Disease Heterogeneity and Clonal Evolution

A critical feature is the marked inter-patient diversity and intra-clonal heterogeneity 2, 7. Even within a single patient, multiple subclones exist with different genetic profiles, which:

• Explains variable clinical presentations and outcomes
• Drives treatment resistance and disease relapse
• Necessitates risk stratification based on genetic features
• Influences therapeutic decision-making at diagnosis and relapse 1

Progression from Precursor States

The disease typically evolves through stages 3, 2:

1. MGUS (Monoclonal Gammopathy of Undetermined Significance): Stable precursor state with <10% plasma cells, no end-organ damage
2. Smoldering Myeloma: ≥10% clonal plasma cells or M-protein ≥3 g/dL, but still no CRAB features—represents a heterogeneous state where approximately two-thirds have MGUS biology and one-third have early MM
3. Symptomatic Multiple Myeloma: Presence of CRAB criteria or other myeloma-defining events

The transition from precursor states to symptomatic disease requires accumulation of secondary genetic events that activate proliferative pathways and disable tumor suppressor mechanisms 4, 2.

Key Clinical Pitfall

Not all "newly diagnosed" myeloma is biologically equivalent—some patients have slow evolution from MGUS over months to years, while others present with highly aggressive disease reflecting advanced clonal evolution and high-risk genetic features 1. This biological heterogeneity mandates genetic testing at diagnosis to stratify risk and guide treatment intensity 1.